Today's After-Hours Stock Movers

PAVmed Inc. (Nasdaq: PAVM) 12.4% LOWER; announced that it is commencing an underwritten public offering of its common stock. PAVmed also expects to grant to the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering

EverQuote (NASDAQ: EVER) 12.3% HIGHER; reported Q4 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $91.79 million. EverQuote sees Q1 2021 revenue of $100-102 million.

ZoomInfo Technologies Inc. (NASDAQ: ZI) 10.6% HIGHER; reported Q4 EPS of $0.12, $0.02 better than the analyst estimate of $0.10. Revenue for the quarter came in at $139.7 million versus the consensus estimate of $130.32 million. ZoomInfo Technologies Inc. sees Q1 2021 EPS of $0.10-$0.12, versus the consensus of $0.10. ZoomInfo Technologies Inc. sees Q1 2021 revenue of $144-146 million, versus the consensus of $135.75 million. ZoomInfo Technologies Inc. sees FY2021 EPS of $0.47-$0.49, versus the consensus of $0.47. ZoomInfo Technologies Inc. sees FY2021 revenue of $645-655 million, versus the consensus of $602 million.

Five9 (NASDAQ: FIVN) 9.3% HIGHER; reported Q4 EPS of $0.34, $0.11 better than the analyst estimate of $0.23. Revenue for the quarter came in at $127.9 million versus the consensus estimate of $115.26 million. Five9 sees Q1 2021 EPS of $0.12-$0.14, versus the consensus of $0.12. Five9 sees Q1 2021 revenue of $122-123 million, versus the consensus of $115.75 million. Five9 sees FY2021 EPS of $0.75-$0.79, versus the consensus of $0.84. Five9 sees FY2021 revenue of $518.5-521.5 million, versus the consensus of $499.41 million

Frequency Therapeutics, Inc. (NASDAQ: FREQ) 7.4% HIGHER; announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology, a leading peer-reviewed journal focused on disorders of the ear. The data show hearing improvements in adults with acquired sensorineural hearing loss (SNHL) and the first-known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy.

Nautilus (NYSE: NLS) 7% LOWER; reported Q4 EPS of $0.90, $0.15 better than the analyst estimate of $0.75. Revenue for the quarter came in at $189.3 million versus the consensus estimate of $191.73 million.

Cadence Design Systems (NASDAQ: CDNS) 6.3% HIGHER; reported Q4 EPS of $0.83, $0.09 better than the analyst estimate of $0.74. Revenue for the quarter came in at $760 million versus the consensus estimate of $732.01 million. Cadence Design Systems sees Q1 2021 EPS of $0.72-$0.76, versus the consensus of $0.71. Cadence Design Systems sees Q1 2021 revenue of $710-730 million, versus the consensus of $703 million. Cadence Design Systems sees FY2021 EPS of $2.95-$3.05, versus the consensus of $2.88. Cadence Design Systems sees FY2021 revenue of $2.86-2.92 million, versus the consensus of $2.83 million.

Green Dot (NYSE: GDOT) 4% LOWER; reported Q4 EPS of $0.31, $0.13 better than the analyst estimate of $0.18. Revenue for the quarter came in at $274.5 million versus the consensus estimate of $257.63 million. Green Dot sees FY2021 EPS of $2.06-$2.15, versus the consensus of $2.22. Green Dot sees FY2021 revenue of $1.23-1.25 billion, versus the consensus of $1.24 billion.

AMC Entertainment (NYSE: AMC) 4% HIGHER; will reopen all 13 of our theatres in New York City beginning March 5th.

Boise Cascade (NYSE: BCC) 2.8% HIGHER; reported Q4 EPS of $0.67, may not compare to the analyst estimate of $1.08. Revenue for the quarter came in at $1.47 billion versus the consensus estimate of $1.34 billion.